دورية أكاديمية
SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
| العنوان: | SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. |
|---|---|
| المؤلفون: | Oberemok VV; V.I. Vernadsky Crimean Federal University, Simferopol, Russia., Laikova KV; V.I. Vernadsky Crimean Federal University, Simferopol, Russia., Yurchenko KA; V.I. Vernadsky Crimean Federal University, Simferopol, Russia., Marochkin NA; V.I. Vernadsky Crimean Federal University, Simferopol, Russia., Fomochkina II; V.I. Vernadsky Crimean Federal University, Simferopol, Russia., Kubyshkin AV; V.I. Vernadsky Crimean Federal University, Simferopol, Russia. kubyshkin_av@mail.ru. |
| المصدر: | Inflammation research : official journal of the European Histamine Research Society ... [et al.] [Inflamm Res] 2020 Sep; Vol. 69 (9), pp. 801-812. Date of Electronic Publication: 2020 Jul 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9508160 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1420-908X (Electronic) Linking ISSN: 10233830 NLM ISO Abbreviation: Inflamm Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : Birkhäuser, c1995- |
| مواضيع طبية MeSH: | Viral Vaccines*, Betacoronavirus/*genetics , Coronavirus Infections/*immunology , Oligodeoxyribonucleotides/*immunology , Pneumonia, Viral/*immunology, Adjuvants, Immunologic ; B-Lymphocytes/virology ; Betacoronavirus/immunology ; COVID-19 ; COVID-19 Vaccines ; Coronavirus Infections/prevention & control ; Coronavirus Infections/virology ; Cytokines/immunology ; Genome, Viral ; HIV/genetics ; Hepacivirus/genetics ; Humans ; Immunity, Humoral ; Immunologic Memory ; Inflammation ; Mutation ; Orthomyxoviridae/genetics ; Pandemics/prevention & control ; Phosphorothioate Oligonucleotides/immunology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/virology ; SARS-CoV-2 ; T-Lymphocytes/virology |
| مستخلص: | During the current COVID-19 pandemic, the global ratio between the dead and the survivors is approximately 1 to 10, which has put humanity on high alert and provided strong motivation for the intensive search for vaccines and drugs. It is already clear that if we follow the most likely scenario, which is similar to that used to create seasonal influenza vaccines, then we will need to develop improved vaccine formulas every year to control the spread of the new, highly mutable coronavirus SARS-CoV-2. In this article, using well-known RNA viruses (HIV, influenza viruses, HCV) as examples, we consider the main successes and failures in creating primarily highly effective vaccines. The experience accumulated dealing with the biology of zoonotic RNA viruses suggests that the fight against COVID-19 will be difficult and lengthy. The most effective vaccines against SARS-CoV-2 will be those able to form highly effective memory cells for both humoral (memory B cells) and cellular (cross-reactive antiviral memory T cells) immunity. Unfortunately, RNA viruses constantly sweep their tracks and perhaps one of the most promising solutions in the fight against the COVID-19 pandemic is the creation of 'universal' vaccines based on conservative SARS-CoV-2 genome sequences (antigen-presenting) and unmethylated CpG dinucleotides (adjuvant) in the composition of the phosphorothioate backbone of single-stranded DNA oligonucleotides (ODN), which can be effective for long periods of use. Here, we propose a SARS-CoV-2 vaccine based on a lasso-like phosphorothioate oligonucleotide construction containing CpG motifs and the antigen-presenting unique ACG-containing genome sequence of SARS-CoV-2. We found that CpG dinucleotides are the most rare dinucleotides in the genomes of SARS-CoV-2 and other known human coronaviruses, and hypothesized that their higher frequency could be responsible for the unwanted increased lethality to the host, causing a 'cytokine storm' in people who overexpress cytokines through the activation of specific Toll-like receptors in a manner similar to TLR9-CpG ODN interactions. Interestingly, the virus strains sequenced in China (Wuhan) in February 2020 contained on average one CpG dinucleotide more in their genome than the later strains from the USA (New York) sequenced in May 2020. Obviously, during the first steps of the microevolution of SARS-CoV-2 in the human population, natural selection tends to select viral genomes containing fewer CpG motifs that do not trigger a strong innate immune response, so the infected person has moderate symptoms and spreads SARS-CoV-2 more readily. However, in our opinion, unmethylated CpG dinucleotides are also capable of preparing the host immune system for the coronavirus infection and should be present in SARS-CoV-2 vaccines as strong adjuvants. |
| References: | Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–2. (PMID: 32284615) Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med. 2011;1:a007252. (PMID: 222291223234456) Kenney RT, Cross AS. Adjuvants for the future. In: Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R, editors. New Generation Vaccines. New York: Informa Healthcare USA, Inc.; 2010. p. 250–262. Pulendran B, Powell J, Flavell RA. Modulating vaccine responses with innate immunity. In: Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R, editors. New Generation Vaccines. New York: Informa Healthcare USA, Inc.; 2010. p. 183–190. Paltrinieri S, Cammarata MP, Cammarata G, Comazzi S. Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis. Vet Immunol Immunopathol. 1998;65:205–20. (PMID: 98398757119882) Loa CC, Lin TL, Wu CC, Bryan T, Thacker HL, Hooper T, Schrader D. Humoral and cellular immune responses in turkey poults infected with turkey coronavirus. Poult Sci. 2001;80:1416–24. (PMID: 11599699) He Y, Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol. 2005;18:327–32. (PMID: 16035944) Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, Chen X, Liu YX, Gao H, Jia YP. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther (Lond). 2007;12:1107–13. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M. VRC 301 Study Team A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–433. (PMID: 188240602612543) Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020;323(15):1502–3. (PMID: 704785232105304) Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3. (PMID: 320758777164637) ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3:e237. (PMID: 167964011483912) Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9:382–5. (PMID: 320650557048180) Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA. 2017;114:E7348–E73577357. (PMID: 288079985584442) Wong S-S, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26:476–92. (PMID: 238243693719499) Ran Z, Shen H, Lang Y, Kolb EA, Turan N, Zhu L, et al. Domestic pigs are susceptible to infection with influenza B viruses. J Virol. 2015;89(9):4818–26. (PMID: 256737274403465) Heo JY, Song JY, Noh JY, Choi MJ, Yoon JG, Lee SN, Cheong HJ, Kim WJ. Effects of influenza immunization on pneumonia in the elderly. Hum Vacc Immuno. 2017;1:744–9. Siriwardena AN. Increasing evidence that influenza is a trigger for cardiovascular disease. J Infect Dis. 2012;206:1636–8. (PMID: 23048169) Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel). 2015;3(2):373–89. Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015;14(10):1313–29. (PMID: 26289975) Types of seasonal influenza vaccine. World Health Organ. https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine . Accessed 5 May 2020. Uchida T. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine. Microbiol Immunol. 2011;55:19–27. (PMID: 21175770) Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, Baxter R, Belongia EA, Weintraub E. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons. Pharmacoepidemiol Drug Saf. 2016;25(8):928–34. (PMID: 27037540) Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev. 2017;17:30001–11. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15:967–76. (PMID: 26954563) El Zowalaty ME, Järhult JD. From SARS to COVID-19: a previously unknown SARS-CoV-2 virus of pandemic potential infecting humans–Call for a One Health approach. One Health. 2020;10:1–24. Parrish CR, Murcia PR, Holmes EC. Influenza virus reservoirs and intermediate hosts: dogs, horses, and new possibilities for influenza virus exposure of humans. J Virol. 2015;89(6):2990–4. (PMID: 25540375) Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, editor. Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 1881–1952. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic Cold spring Harbor perspectives in medicine. Medicine. 2011;6:8–41. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1994;4(393):648–59. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA. 2000;97:9026–31. (PMID: 1092205816815) Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell. 1998;93:665–71. (PMID: 9630210) Overbaugh J, Morris L. The antibody response against HIV-1 Cold Spring Harb. Perspect Med. 2012;2:7–39. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology. 2008;375:529–38. (PMID: 18433824) Dreja H, O’Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A, D’Souza C, Leber W, et al. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol. 2010;91:2794–803. (PMID: 20685933) Preston BD. Reverse transcriptase fidelity and HIV-1 variation. Science. 1997;275:228–9. (PMID: 8999549) Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123–6. (PMID: 7816094) Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, da Silva J, Allen TM, Horton H, Venham JE, Rudersdorf JA, Vogel T, Pauza CD, Bontrop RE, DeMars R, Sette A, Hughes AL, Watkins DI. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus. Env Nef Nat Med. 1999;5:1270–6. (PMID: 10545993) Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 1999;13:137–62. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19–42. (PMID: 11714622) McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS. 2000;14(3):31–44. Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 2002;37:684–95. (PMID: 12399239) Pybus OG, Theze J. Hepacivirus cross-species transmission and the origins of the hepatitis C virus. Curr Opin Virol. 2006;16:1–7. Drexler JF, Corman VM, Müller MA, Lukashev AN, Gmyl A, Coutard B, Adam A, Ritz D, Leijten LM, van Riel D, Kallies R, Klose SM, Gloza-Rausch F, Binger T, Annan A, Adu-Sarkodie Y, Oppong S, Bourgarel M, Rupp D, Hoffmann B, Schlegel M, Kümmerer BM, Krüger DH, Schmidt-Chanasit J, Setién AA, Cottontail VM, Hemachudha T, Wacharapluesadee S, Osterrieder K, Bartenschlager R, Matthee S, Beer M, Kuiken T, Reusken C, Leroy EM, Ulrich RG, Drosten C. Evidence for novel hepaciviruses in rodents. PLoS Pathog. 2013;9:e1003438. (PMID: 238188483688547) Baechlein C, Fischer N, Grundhoff A, et al. Identification of a Novel Hepacivirus in Domestic Cattle from Germany. J Virol. 2015;89(14):7007–155. (PMID: 259266524473572) Lauck M, Sibley SD, Lara J, Purdy MA, Khudyakov Y, Hyeroba D, et al. A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old World primate. J of Virol. 2013;87:8971–81. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:87–99. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–48. (PMID: 283199965486987) WHO. Global Hepatitis Report Geneva. Switzerland: WHO; 2017. Gravitz L. Introduction: a smouldering public-health crisis. Nature. 2011;474:2–4. Cox AL. MEDICINE. Global control of hepatitis C virus. Science. 2015;349:790–1. (PMID: 26293940) Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25:220–7. (PMID: 293160305841922) Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367–73. (PMID: 206193822923449) Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE. 2013;8:e59776. (PMID: 235272663602185) Shoukry NH, Hepatitis C. Vaccines, antibodies, and T Cells. Front Immunol. 2018;9:9. Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. (PMID: 249826564058636) Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol. 2008;82:5. Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology. 2006;44:1098–109. https://doi.org/10.1002/hep.21365 . (PMID: 10.1002/hep.2136517058243) Bengsch B, Spangenberg HC, Kersting N, Neumann-Haefelin C, Panther E, Von Weizsacker F, et al. Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol. 2007;81:945–53. (PMID: 17079288) Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, De Re V, et al. The frequency of CD127+ HCV-specific T cells but not the expression of exhaustion markers predict the outcome of acute hepatitis C virus infection. J Virol. 2013;87(8):4772–7. (PMID: 233887063624391) Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11:e1005177. (PMID: 264855194618999) Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014;105(100):100–11. (PMID: 245830334034163) Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2008;14:25–7. (PMID: 18064037) Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA. 2012;109:6205–10. (PMID: 224929643341081) Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight. 2017;2(9):e92872. (PMID: 5414559) Batista-Duharte A, Sendra L, Herrero MJ, Téllez-Martínez D, Carlos IZ, Aliño SF. Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement. Biomolecules. 2020;10(2):316. (PMID: 7072586) Myhr AI. DNA Vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol. 2017;22:79–88. (PMID: 27705898) Ghaffarifar F. Plasmid DNA vaccines: where are we now? Drugs Today Barc. 2018;54:315–33. (PMID: 29911696) Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25:152–9. (PMID: 23735226) Kramps T, Elbers K. Introduction to RNA vaccines. Methods Mol Biol. 2017;1499:1–11. (PMID: 27987140) Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10:499–511. (PMID: 215066473108434) Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32:6377–89. (PMID: 249758124252359) Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 1992;36:983–97. (PMID: 1281260) Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546–9. (PMID: 7700380) Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2020;20:197–21616. Murad YM, Clay TM. CpG Oligodeoxynucleotides as TLR9 Agonists. BioDrugs. 2009;23:361–75. (PMID: 19894778) Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009;61:195–204. (PMID: 19211030) Campbell JD. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 2017;1494:15–27. (PMID: 27718183) Guerrier T, Youinou P, Pers JO, Jamin C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun. 2012;39:173–9. (PMID: 22695187) Sacher T, Knolle P, Nichterlein T, Arnold B, Hämmerling GJ, Limmer A. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol. 2002;32:3628–37. (PMID: 12516551) Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1–3):118–28. (PMID: 248454624125530) Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004;10:S88–S97. (PMID: 155779377096017) Murasko DM, Jiang J. Response of aged mice to primary virus infections. Immunol Rev. 2005;205:285–96. (PMID: 15882361) Gardner EM, Gonzalez EW, Nogusa S, Murasko DM. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine. 2006;24:1609–14. (PMID: 16260072) Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007;3:e5. (PMID: 172220581769406) Williamson JS, Stohlman SA. Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J Virol. 1990;64:4589–92. (PMID: 2166833247935) Roth Y, Chapnik JS, Cole P. Feasibility of aerosol vaccination in humans. Ann Otol Rhinol Laryngol. 2003;112:264–70. (PMID: 12656420) Manjaly Thomas ZR, McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg. 2015;109:175–81. (PMID: 256369504321022) Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020;4:8. Gottlieb J, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, Arcasoy S, DeVincenzo J, Karsten V, Shah S, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35:213–21. (PMID: 26452996) Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5:190–8. (PMID: 14716310) Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, Bauer S, Hochrein H, Wagner H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol. 2005;174:6129–36. (PMID: 15879108) Haas T, Metzger J, Schmitz F, Heit A, Muller T, Latz E, Wagner H. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity. 2008;28:315–23. (PMID: 18342006) Wagner H. The sweetness of the DNA backbone drives Toll-like receptor 9. Curr Opin Immunol. 2008;20:396–400. (PMID: 18656540) Ashman RF, Goeken JA, Latz E, Lenert P. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol. 2011;23:203–14. (PMID: 213936363053407) Glasspool-Malone J, Steenland PR, McDonald RJ, Sanchez RA, Watts TL, Zabner J, Malone RW. DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. J Gene Med. 2002;4:323–32. (PMID: 12112649) Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1:347–55. (PMID: 12489851) Haas T, et al. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity. 2008;28:315–23. (PMID: 18342006) Atkinson NJ, Witteveldt J, Evans DJ, Simmonds P. The influence of CpG and UpA dinucleotide frequencies on RNA virus replication and characterization of the innate cellular pathways underlying virus attenuation and enhanced replication. Nucleic Acids Res. 2014;42:4527–45. (PMID: 244701463985648) Greenbaum BD, Rabadan R, Levine AJ. Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune system. PLoS ONE. 2009;4(6):e5969. (PMID: 195363382694999) Lobo FP, Mota BE, Pena SD, Azevedo V, Macedo AM, Tauch A, Machado CR, Franco GR. Virus-host coevolution: common patterns of nucleotide motif usage in Flaviviridae and their hosts. PLoS ONE. 2009;4(7):e6282. (PMID: 196179122707012) Greenbaum BD, Levine AJ, Bhanot G, Rabadan R. Patterns of evolution and host gene mimicry in influenza and other RNA viruses. PLoS Pathog. 2008;4:e1000079. (PMID: 185356582390760) Jimenez-Baranda S, Greenbaum B, Manches O, Handler J, Rabadán R, et al. Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells. J Virol. 2011;85:3893–904. (PMID: 213071983126114) Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000;21:521–6. (PMID: 11071532) Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157(5):1840–5. (PMID: 8757300) Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992;148(12):4072–6. (PMID: 1376349) Rankin R, Pontarollo R, Iannou X, Krieg AM, Hecker R. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001;11:333–40. (PMID: 11763350) Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164(2):944–53. (PMID: 10623843) Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell H, Davis HL, Krieg AM. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164(3):1617–24. (PMID: 10640783) Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest. 1996;98(5):1119–29. (PMID: 8787674507533) Krieg AM. CpG Motifs in Bacterial DNA and Their Immune Effects. Ann Rev Immunol. 2002;20:709–60. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 1987;3:342–7. Han J, Zhu Z, Hsu C, Finley WH. Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Res Dev. 1994;4(1):53–655. (PMID: 8061516) Shpaer EG, Mullins JI. Selection against CpG dinucleotides in lentiviral genes: a possible role of methylation in regulation of viral expression. Nucleic Acids Res. 1990;18(19):5793–7. (PMID: 2170945332316) Krieg AM. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996;4(2):73–6. (PMID: 8820571) Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents–is the bullet really magical? Science. 1993;261(5124):1004–122. (PMID: 8351515) Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides [editorial]. Antisense Res Dev. 1994;4(2):67–9. (PMID: 7950301) Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. (PMID: 32105090) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506. (PMID: 31986264) Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 2008;4:e1000115. (PMID: 186706482483250) Wang SY, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M, Kido H. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis. 2010;202:991–1001. (PMID: 20731583) Cheng XW, Lu JA, Wu CL, Yi LN, Xie X, Shi XD, Fang SS, Zan H, Kung HF, He ML. Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm. Respir Physiol Neurobiol. 2011;175:185–7. (PMID: 21075220) |
| فهرسة مساهمة: | Keywords: COVID-19 pandemic; CpG motif; Phosphorothioate oligonucleotides; SARS-CoV-2; Vaccine |
| المشرفين على المادة: | 0 (Adjuvants, Immunologic) 0 (COVID-19 Vaccines) 0 (CPG-oligonucleotide) 0 (Cytokines) 0 (Oligodeoxyribonucleotides) 0 (Phosphorothioate Oligonucleotides) 0 (Viral Vaccines) |
| تواريخ الأحداث: | Date Created: 20200714 Date Completed: 20200810 Latest Revision: 20220905 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7354743 |
| DOI: | 10.1007/s00011-020-01377-3 |
| PMID: | 32656668 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!